Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 01 (2026)
International Multidisciplinary Journal for Research & Development

Articles

GENETIC MECHANISMS AND THE ROLE OF SUSCEPTIBILITY GENES IN AMYOTROPHIC LATERAL SCLEROSIS: PATHOGENIC PATHWAYS, CLINICAL IMPLICATIONS, AND EMERGING TARGETS

Published 2026-01-25

  • Akbarova Saida Bakhtiyorova

Akbarova Saida Bakhtiyorova
PhD, associate professor of Normal physiology

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, leading to paralysis and eventual respiratory failure. While the disease is clinically heterogeneous, genetic factors play a central role in its pathogenesis. Approximately 10% of ALS cases are familial (fALS), with mutations in several key genes including SOD1, C9orf72, TARDBP, and FUS. An increasing body of research has identified additional susceptibility genes and risk loci that contribute to sporadic ALS (sALS) through dysregulation of RNA metabolism, proteostasis, cytoskeletal integrity, and immune responses. This study critically examines the genetic architecture of ALS, explores molecular pathways impacted by pathogenic variants, and evaluates emerging genetic targets for therapeutic intervention. Through comprehensive genomic analysis, we identify novel genes implicated in ALS and provide an integrative model linking genetic variation to neurodegeneration.

Keywords

Amyotrophic lateral sclerosis, neurodegeneration, genetic factors, SOD1, C9orf72, TARDBP, FUS.

PDF

References

  1. Al-Chalabi A, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Brain 2021.
  2. Abati E., Bresolin N., Comi G., Corti S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). // Expert Opin Ther Targets. – 2020; 24 (4): 295–310.
  3. Agah E., Saleh F., Sanjari Moghaddam H., et al. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta-analysis // Syst. Rev. – 2018; 7: 237.
  4. Akaishi T., Tateyama M., Kato K., et al. An autopsy case involving a 12-year history of amyotrophic lateral sclerosis with CIDP-like polyneuropathy // Intern Med. – 2014; 53(12): 1371–1375.
  5. Al-Chalabi, A. Amyotrophic lateral sclerosis: moving towards a new classification system / A. Al-Chalabi, O. Hardiman, M.C. Kiernan // Lancet Neurol. – 2016. – Vol. 15. – № 11. – rr. 1182–1194.
  6. Bello-Haas V.D. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights // Degener Neurol Neuromuscul Dis. – 2018; 8: 45–54.
  7. Benbrika S., Desgranges B., Eustache F., Viader F. Cognitive, Emotional and Psychological Manifestations in Amyotrophic Lateral Sclerosis at Baseline and Overtime: A Review // Front Neurosci. – 2019; 13: 951.
  8. Bhandari R., Kuhad A., Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis // Drugs Today (Barc). – 2018; 54: 349–60.
  9. Bledsoe M.J., Rechtman L., Wagner L., Mehta, et al. Analysis of biospecimen demand and utilization of samples from the National Amyotrophic Lateral Sclerosis Biorepository // Biopreserv Biobanking. – 2021; 19(5): 432–437.
  10. Boostani R., Olfati N., Shamshiri H., et al. Iranian clinical practice guideline for amyotrophic lateral sclerosis // Front Neurol. – 2023 Jun 2; 14: 1154579.
  11. Capozzella A., Sacco C., Chighine A., Loreti B., Scala B., et al. Work related etiology of amyotrophic lateral sclerosis (ALS): a meta-analysis // Ann Ig. 2014; 26: 456–472.
  12. Cedarbaum M.D., Deepak A. Rao, Hiroto Hatabu, Katherine H. Walker. A Bumpy Road to Diagnosis // N Engl J Med. – 2023; 389: 72–77.
  13. Chew S., Atassi N. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis // Front Neurol. – 2019; 10: 135.
  14. Chiò A., Logroscino G., Traynor B., Collins J., Simeone J., Goldstein L., White L. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature // Neuroepidemiology. – 2013; 41: 118–130. [CrossRef].
  15. Ciura S., Sellier C., Campanari M.L., Charlet-Berguerand N., Kabashi E. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway // Autophagy. – 2016.
  16. Marinelli G, et al. Emerging ALS genes and pathways. Neurobiol Aging 2023.
  17. Montuschi A., Iazzolino B., Calvo A., Moglia C., et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy // Journal Neurol Neurosurg Psychiatry. – 2015; 86(2): 168–173.
  18. Murdock B.J., Famie J.P., Piecuch C.E., et al. NK cells associate with ALS in a sex- and age-dependent manner // JCI Insight. – 2021; 6(11): 1–15.
  19. Nelson L.M., Topol B., Kaye W., Raymond J. et al. Evaluation of the completeness of ALS Case Ascertainment in the US National ALS Registry: application of the capture-recapture method // Neuroepidemiology. – 2022; 56: 104–114.
  20. Oberstadt M., Claßen J., Arendt T., Holzer M. TDP-43 and Cytoskeletal Proteins in ALS // Mol. Neurobiol. – 2018; 55 (4): 3143–3151.

Downloads

Download data is not yet available.